Upstream Bio, Inc.
Support and Resistance Levels
Past performance
News About UPB
All events for UPB
All deals for UPB
Financial Ratios
Financial Statements
UPB vs Sector & Peers
About Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts. Website upstreambio.com
Headquarters Waltham, MA, US